Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Commercial Officer | March 10, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date March 10, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 4,475 |
Reported balance
After 2026-03-10 transaction · row 1
1 source rowRow 1 · 2026-03-10 · Purchase · Acquired 4,475 · Balance 4,475 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2026 Filed Mar 10, 2026 22:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | PurchaseCommon Stock, par value $0.00001 per share | 4,475 | $33.50 | $149,912.50 |
DisclosureSEC source: 0001193125-26-100581 · ownership.xml · nonDerivative · entry 1 Aubuchon Neil William · CIK 0002106781 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Read SEC document |
| January 12, 2026 Filed Jan 27, 2026 00:57 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $31.76 | $0.00 |
DisclosureSEC source: 0001193125-26-023030 · ownership.xml · derivative · entry 1 Aubuchon Neil William · CIK 0002106781 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.